A detailed history of Brevan Howard Capital Management LP transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 99,757 shares of IBRX stock, worth $341,168. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,757
Holding current value
$341,168
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$2.56 - $6.17 $255,377 - $615,500
99,757 New
99,757 $255,000
Q2 2024

Aug 14, 2024

BUY
$4.82 - $9.15 $466,407 - $885,399
96,765 New
96,765 $611,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.37B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.